Friday , October 22 2021

ADVICIENNE: Successful listing of its shares in the Euronext Brussels liquidation market


French biotechnology Advicenne has announced the successful listing of its shares on the regulated market of Euronext Brussels. Today, Advicenne's common shares are listed on Euronext Paris, its main market for quotation, and on Euronext Brussels, with unchanged identifiers. Advicenne now has a cross-listing in the two largest Euronext markets for Bioscience companies to increase the visibility of its shares in Belgium and Europe.

This listing on Euronext Brussels is also part of the clinical development of the company conducting a phase II / III clinical study in Belgium with ADV7103, its main product, for the treatment of cystinuria, a rare nephrological disease.

Paul Michalet, Chief Financial Officer of Advicenne, commented: "We are very pleased with the success of this cross-listing in the Euronext Brussels and Paris markets, which will increase Advicenne's visibility in Europe and increase the liquidity of the stock market."

Clinical Trials (Phases I, II, III)
Phase I: small molecule test in humans to evaluate their safety, tolerance, metabolic and pharmacological properties Phase II: assessment of tolerance and efficacy in several hundred patients to identify side effects. III: evaluation of the overall benefit / risk ratio for several thousand patients.

Copyright 2019 AOF
All rights of reproduction and representation reserved (Legal notice)

Source link